

Literaturverzeichnis

Hamburger Ärzteblatt 01 | 2020

Seite 1

Weidestr. 122 b

22083 Hamburg

Redaktion

E-Mail: verlag@aekhh.de

Tel.: (040) 20 22 99 – 205

Fax: (040) 20 22 99 – 400

S. 12 – 16: Interventionelle Therapie der pAVK *Von PD Dr. Hans Krankenberg*

1. Song P, Rudan D, Zhu Y, et al. Global, regional, and national prevalence and risk factors for peripheral artery disease in 2015: an updated systematic review and analysis. *Lancet Glob Health*. 2019; 7(8): e1020-e30.
2. Fowkes FG, Aboyans V, Fowkes FJ, et al. Peripheral artery disease: epidemiology and global perspectives. *Nat Rev Cardiol*. 2017; 14(3): 156-70.
3. Sartipy F, Sigvant B, Lundin F, et al. Ten Year Mortality in Different Peripheral Arterial Disease Stages: A Population Based Observational Study on Outcome. *Eur J Vasc Endovasc Surg*. 2018; 55(4): 529-36.
4. Rosenbloom MS, Flanigan DP, Schuler JJ, et al. Risk factors affecting the natural history of intermittent claudication. *Arch Surg*. 1988; 123(7): 867-70.
5. Norgren L, Hiatt WR, Dormandy JA, et al. Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II). *J Vasc Surg*. 2007; 45 Suppl S: S5-67.
6. Abaraogu UO, Ezenwankwo EF, Dall PM, et al. Living a burdensome and demanding life: A qualitative systematic review of the patients experiences of peripheral arterial disease. *PLoS One*. 2018; 13(11): e0207456.
7. Pande RL, Perlstein TS, Beckman JA, et al. Secondary prevention and mortality in peripheral artery disease: National Health and Nutrition Examination Study, 1999 to 2004. *Circulation*. 2011; 124(1): 17-23.
8. Aboyans V, Ricco JB, Bartelink MEL, et al. 2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS): Document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteries Endorsed by: the European Stroke Organization (ESO) The Task Force for the Diagnosis and Treatment of Peripheral Arterial Diseases of the European Society of Cardiology (ESC) and of the European Society for Vascular Surgery (ESVS). *Eur Heart J*. 2018; 39(9): 763-816.
9. Conte MS, Bradbury AW, Kolh P, et al. Global Vascular Guidelines on the Management of Chronic Limb-Threatening Ischemia. *Eur J Vasc Endovasc Surg*. 2019; 58(15): S1-S109 e33.
10. Krankenberg H, Zeller T, Ingwersen M, et al. Self-Expanding Versus Balloon-Expandable Stents for Iliac Artery Occlusive Disease: The Randomized ICE Trial. *JACC Cardiovasc Interv*. 2017; 10(16): 1694-704.
11. Indes JE, Pfaff MJ, Farrokhhyar F, et al. Clinical outcomes of 5358 patients undergoing direct open bypass or endovascular treatment for aortoiliac occlusive disease: a systematic review and meta-analysis. *J Endovasc Ther*. 2013; 20(4): 443-55.
12. Mwipatayi BP, Sharma S, Daneshmand A, et al. Durability of the balloon-expandable covered versus bare-metal stents in the Covered versus Balloon Expandable Stent Trial (COBEST) for the treatment of aortoiliac occlusive disease. *J Vasc Surg*. 2016; 64(1): 83-94 e1.
13. Piazza M, Squizzato F, Dall'Antonia A, et al. Editor's Choice - Outcomes of Self Expanding PTFE Covered Stent Versus Bare Metal Stent for Chronic Iliac Artery Occlusion in Matched Cohorts Using Propensity Score Modelling. *Eur J Vasc Endovasc Surg*. 2017; 54(2): 177-85.
14. Inui T, Deshpande R, Lane JS, et al. External Iliac Occlusion Does Not Preclude Endovascular Management of Aortoiliac Disease-Technique and Evolution of Therapy. *Ann Vasc Surg*. 2018; 53: 184-9.
15. Taeymans K, Groot Jebbink E, Holewijn S, et al. Three-year outcome of the covered endovascular reconstruction of the aortic bifurcation technique for aortoiliac occlusive disease. *J Vasc Surg*. 2018; 67(5): 1438-47.
16. Stahlhoff S, Donas KP, Torsello G, et al. Drug-Eluting vs Standard Balloon Angioplasty for Iliac Stent Restenosis: Midterm Results. *J Endovasc Ther*. 2015; 22(3): 314-8.

Literaturverzeichnis

Hamburger Ärzteblatt 01 | 2020

Seite 2

Weidestr. 122 b
22083 Hamburg
Redaktion

E-Mail: verlag@aekhh.de

Tel.: (040) 20 22 99 – 205

Fax: (040) 20 22 99 – 400

17. Nguyen BN, Amdur RL, Abugideiri M, et al. Postoperative complications after common femoral endarterectomy. *J Vasc Surg.* 2015; 61(6): 1489-94 e1.
18. Jia X, Sun ZD, Patel JV, et al. Systematic review of endovascular intervention and surgery for common femoral artery atherosclerotic disease. *Br J Surg.* 2019; 106(1): 13-22.
19. Deloose K, Martins I, Neves C, et al. Endovascular treatment for the common femoral artery: is there a challenger to open surgery? *J Cardiovasc Surg (Torino).* 2019; 60(1): 8-13.
20. Schneider PA, Laird JR, Tepe G, et al. Treatment Effect of Drug-Coated Balloons Is Durable to 3 Years in the Femoropopliteal Arteries: Long-Term Results of the IN.PACT SFA Randomized Trial. *Circ Cardiovasc Interv.* 2018; 11(1): e005891.
21. Ichihashi S, Shibata T, Fujimura N, et al. Vessel Calcification as a Risk Factor for In-Stent Restenosis in Complex Femoropopliteal Lesions After Zilver PTX Paclitaxel-Coated Stent Placement. *J Endovasc Ther.* 2019: 1526602819860124.
22. Fusaro M, Cassese S, Ndrepepa G, et al. Paclitaxel-coated balloon or primary bare nitinol stent for revascularization of femoropopliteal artery: a meta-analysis of randomized trials versus uncoated balloon and an adjusted indirect comparison. *Int J Cardiol.* 2013; 168(4): 4002-9.
23. Cassese S, Wolf F, Ingwersen M, et al. Drug-Coated Balloon Angioplasty for Femoropopliteal In-Stent Restenosis. *Circ Cardiovasc Interv.* 2018; 11(12): e007055.
24. Kayssi A, Al-Jundi W, Papia G, et al. Drug-eluting balloon angioplasty versus uncoated balloon angioplasty for the treatment of in-stent restenosis of the femoropopliteal arteries. *Cochrane Database Syst Rev.* 2019; 1: CD012510.
25. Muller-Hulsbeck S, Keirse K, Zeller T, et al. Long-Term Results from the MAJESTIC Trial of the Eluvia Paclitaxel-Eluting Stent for Femoropopliteal Treatment: 3-Year Follow-up. *Cardiovasc Intervent Radiol.* 2017; 40(12): 1832-8.
26. Dake MD, Ansel GM, Jaff MR, et al. Durable Clinical Effectiveness With Paclitaxel-Eluting Stents in the Femoropopliteal Artery: 5-Year Results of the Zilver PTX Randomized Trial. *Circulation.* 2016; 133(15): 1472-83; discussion 83.
27. Ding Y, Zhou M, Wang Y, et al. Comparison of Drug-Eluting Stent with Bare-Metal Stent Implantation in Femoropopliteal Artery Disease: A Systematic Review and Meta-Analysis. *Ann Vasc Surg.* 2018; 50: 96-105.
28. Werner M, Paetzold A, Banning-Eichenseer U, et al. Treatment of complex atherosclerotic femoropopliteal artery disease with a self-expanding interwoven nitinol stent: midterm results from the Leipzig SUPERA 500 registry. *EuroIntervention.* 2014; 10(7): 861-8.
29. Rastan A, Krankenberg H, Baumgartner I, et al. Stent placement vs. balloon angioplasty for popliteal artery treatment: two-year results of a prospective, multicenter, randomized trial. *J Endovasc Ther.* 2015; 22(1): 22-7.
30. San Norberto EM, Flota CM, Fidalgo-Domingos L, et al. –Real World Results of Supera Stent Implantation for Popliteal Artery Atherosclerotic Lesions: 3-Years Outcome. *Ann Vasc Surg.* 2019
31. Zhou Y, Lin S, Zhang Z, et al. A Network Meta-analysis of Randomized Controlled Trials Comparing Treatment Modalities for Infrapopliteal Lesions in Critical Limb Ischemia. *Ann Vasc Surg.* 2019
32. Zhang J, Xu X, Kong J, et al. Systematic Review and Meta-Analysis of Drug-Eluting Balloon and Stent for Infrapopliteal Artery Revascularization. *Vasc Endovascular Surg.* 2017; 51(2): 72-83.
33. Spreen MI, Martens JM, Knippenberg B, et al. Long-Term Follow-up of the PADI Trial: Percutaneous Transluminal Angioplasty Versus Drug-Eluting Stents for Infrapopliteal Lesions in Critical Limb Ischemia. *J Am Heart Assoc.* 2017; 6(4).

Literaturverzeichnis

Hamburger Ärzteblatt 01 | 2020

Seite 3

Weidestr. 122 b

22083 Hamburg

Redaktion

E-Mail: verlag@aekeh.de

Tel.: (040) 20 22 99 – 205

Fax: (040) 20 22 99 – 400

S. 22 – 23: Bauchhypnose verlängert beschwerdefreie Intervalle *Interview mit Dipl.-Psych. Georg Tecker*

1. Tecker G, Derra C, Federschmidt H. Psychotherapie bei Darmerkrankungen. In: Bauchredner, Mitgliederzeitschrift der DCCV e.V. Ausgabe 4, 2016
2. Tecker G (Hrsg). Gut leben mit Morbus Crohn und Colitis ulcerosa, Stuttgart, 2013
3. Harrer ME. Hypnose und Achtsamkeit. Zwei Schwestern auf dem Tandem. Heidelberg, 2018
4. Milne B, Joachim G, et al. A stress management programme for inflammatory bowel disease patients. Journal of advanced nursing. 1986;11 (5):561–567.
5. Keefer L, Taft TH, Kiebles JL, Martinovich Z, Barrett TA, Palsson OS. Gut-directed hypnotherapy significantly augments clinical remission in quiescent ulcerative colitis. Aliment Pharmacol Ther. 2013;38(7):761-71.
6. Tecker G. Kurze Einschätzung zur Bauchhypnose-Pilotstudie von 11.2017 bis 7.2018. Vortrag auf Crohn&Colitis-Tag am 5.10.2018 im MVZ für Immunologie in Hamburg-Lokstedt. Veröffentlicht in www.ced-hamburg.de/?id=archiv.
7. Levenstein S, et al. Stress and Exacerbation in Ulcerative Colitis: A Prospective Study of Patients Enrolled in Remission. Am J Gastroenterol. 2000;95: S.1213-20.
8. Danese A, Pariante CM, Caspi A, et al. Childhood maltreatment predicts adult inflammation in a life-course study. Proc Natl Acad Sci USA. 2007;104. 1319-1324.
9. Wilk D. Auf den Schultern des Windes schaukeln, Heidelberg, 2005

S. 24 – 25: Akute Gastritis stellt sich als Kolonkarzinom heraus *Von Dr. Dr. Nursel Saritas*

1. Hofheinz RD, Arnold D, Borner M, Folprecht G, Graeven U, Hebart H, Hegewisch-Becker S, Heinemann V, Meybier T, Pritzkeleit R, Scheithauer W, Thaler J, Weitz J, Wörmann B. Kolonkarzinom ICD-10 C18, Stand Oktober 2018 <https://www.onkopedia.com/de/onkopedia/guidelines/kolonkarzinom/@@guideline/html/index.html>
2. ER Vuik F, AV Nieuwenburg S, Bardou M, Lansdorp-Vogelaar I, Dinis-Ribeiro M, Bento MJ, Zadnik V, Pellisé M, Esteban L, Kaminski MF, Suchanek S, Ngo O, Májek O, Leja M, Kuipers EJ, CW Spaander M. Increasing incidence of colorectal cancer in young adults in Europe over the last 25 years; first published as 10.1136/gutjnl-2018-317592 on 16 May 2019. <https://gut.bmj.com/content/gutjnl/68/10/1820.full.pdf>
3. Aragli M, Soerjomataram I, Bardot A, Ferlay J, Cabasag CJ, Morrison DS, et al. Changes in colorectal cancer incidence in seven high-income countries: a population-based study. The Lancet Volume 4, ISSUE 7, P511-518, July 01, 2019
4. Siegel RL, Fedewa SA, Anderson WF, Miller KD, Ma J, Rosenberg PS, Jemal A. Colorectal Cancer Incidence Patterns in the United States, 1974–2013. JNCI: Journal of the National Cancer Institute, Volume 109, Issue 8, August 2017, djw322! <https://doi.org/10.1093/jnci/djw322>

S. 32 – 33: Hornhautbank hilft, das Sehen wieder zu ermöglichen

Von Univ.-Prof. Dr. Martin Spitzer, Prof. Dr. Klaus Püschel, Dr. Maria K. Casagrande, Dr. Eileen Bigdon

1. Stevens GA, White RA, Flaxman SR, et al. Global prevalence of vision impairment and blindness: magnitude and temporal trends, 1990–2010. Ophthalmology 2013; 120: 2377-2384, DOI: 10.1016/j.ophtha.2013.05.025.
2. Resnikoff S, Pascolini D, Etya'ale D, et al. Global data on visual impairment in the year 2002. Bulletin of the World Health Organization 2004; 82: 844-851, DOI: /S0042-96862004001100009.

Literaturverzeichnis

Hamburger Ärzteblatt 01 | 2020

Seite 4

Weidestr. 122 b
22083 Hamburg
Redaktion

E-Mail: verlag@aekhh.de

Tel.: (040) 20 22 99 – 205

Fax: (040) 20 22 99 – 400

3. Flaxman SR, Bourne RRA, Resnikoff S, et al. Global causes of blindness and distance vision impairment 1990-2020: a systematic review and meta-analysis. *The Lancet Global health* 2017; 5: e1221-e1234, DOI: 10.1016/s2214-109x(17)30393-5.
4. Pineda R. Corneal Transplantation in the Developing World: Lessons Learned and Meeting the Challenge. *Cornea* 2015; 34 Suppl 10: S35-40, DOI: 10.1097/ico.0000000000000567.
5. Lamm V, Hara H, Mammen A, et al. Corneal blindness and xenotransplantation. *Xenotransplantation* 2014; 21: 99-114, DOI: 10.1111/xen.12082.